Insmed to Present at the Cowen and Company 40th Annual Health Care Conference

On February 26, 2020 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020, at 9:20 a.m. ET (Press release, Insmed, FEB 26, 2020, View Source [SID1234554838]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

Thermo Fisher Scientific President and Chief Executive Officer Marc N. Casper Elected Chairman of the Board of Directors

On February 26, 2020 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that its board of directors has elected president and chief executive officer Marc N. Casper, 51, as chairman, effective immediately (Press release, Thermo Fisher Scientific, FEB 26, 2020, View Source [SID1234554837]). Casper will continue in his role as president and chief executive officer, which he has held since October 2009.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company also announced that Thomas Lynch, 65, has been elected lead independent director, effective immediately. Lynch has been a member of Thermo Fisher’s board since May 2009.

Casper succeeds Jim Manzi, 68, who has served as a director since May 2000 and as chairman of the board for 15 years. Manzi will continue to serve as a director on the Thermo Fisher board.

"Marc has demonstrated exceptional leadership of Thermo Fisher Scientific, driving the outstanding execution of a growth strategy that has resulted in significant value creation for our customers, colleagues and shareholders," said Manzi. "Given his contributions to the company’s success, and his insights and expertise as a member of the board, we unanimously selected Marc to also take on the chairman role as Thermo Fisher begins the next decade."

"I am honored to be taking on this additional role at such an exciting time for our company," said Casper. "Together with the board, our leadership team and our 75,000 colleagues around the world, we will continue to execute our proven strategy to create value for all those who have a stake in our success."

Casper continued, "I’ve had the pleasure of knowing and working with Tom for some time, and our board has the highest confidence in him as our lead independent director. He has brought valuable perspective to our board over the last 10 years and we look forward to continuing to benefit from his outstanding leadership skills, financial expertise and international experience."

Lynch has served as chairman of TE Connectivity Ltd. (formerly Tyco Electronics Ltd.), a global industrial technology company, since 2013 and as chief executive officer from January 2006 to March 2017. Prior to that, Lynch was president of Tyco Engineered Products & Services. He previously served as executive vice president of Motorola and president and chief executive officer of Motorola’s Personal Communications sector. Lynch’s board-level experience also includes his current roles as a director of Automated Data Processing Inc. and Cummins Inc.

Cellular Biomedicine Group to Report Fourth Quarter and Full Year 2019 Results on February 28, 2020

On February 26, 2020 Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported that it will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on Friday, February 28, 2020 (Press release, Cellular Biomedicine Group, FEB 26, 2020, View Source [SID1234554836]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will host a conference call and webcast with the investment community on Friday, February 28th at 4:30 p.m. Eastern Time, featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG.

What:

Cellular Biomedicine Fourth Quarter and Full Year 2019 Results Conference Call

Date:

Friday, February 28, 2020

Time:

4:30 p.m. Eastern Time

Live Call:

Toll-Free: 1-877-423-9813

International: 1-201-689-8573

Webcast:

View Source

Replay:

Toll-Free: 1-844-512-2921

International: 1-412-317-6671

Conference ID: 13699688

(Available approximately two hours after the completion of the live call until 11:59 p.m. ET on March 13, 2020)

Quest Diagnostics To Speak At The Barclays Global Healthcare Conference

On February 26, 2020 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami (Press release, Quest Diagnostics, FEB 26, 2020, View Source [SID1234554835]). Mark Guinan, Executive Vice President and CFO, will discuss the company’s vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, March 10, 2020 at 9:30 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until April 9, 2020.

Nordic Nanovector Appoints Dr Lars Nieba as Interim Chief Executive Officer

On February 26, 2020 Nordic Nanovector ASA (OSE: NANO) reported that Dr Lars Nieba has been appointed interim Chief Executive Officer with immediate effect (Press release, Nordic Nanovector, FEB 26, 2020, View Source [SID1234554834]). Dr Nieba, who is currently the Company’s Chief Technology Officer, replaces Eduardo Bravo who as of today has left Nordic Nanovector to pursue other career opportunities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Nieba joined Nordic Nanovector on 1 December 2019 from Bayer AG where he served in various operational and strategic roles, Dr Nieba was most recently responsible for driving Bayer’s Chemistry, Manufacturing and Controls (CMC) strategy for biologicals. He joined Bayer in 2016 following 13 years at F. Hoffmann-La Roche Ltd., where he held various leadership roles in clinical, operations, supply planning, biologics technology and technical business development. Prior Dr Nieba worked for Cytos Biotechnology where he served as Head of Therapeutic Vaccine Research.

Dr Nieba gained a PhD from the Max-Planck-Institute for Biochemistry, München and Institute for Biochemistry at the University of Zürich, and an Executive MBA from the University of St. Gallen, Switzerland.

Jan H. Egberts, MD, Chairman of Nordic Nanovector, commented: "The Board is very pleased to appoint Lars Nieba as Nordic Nanovector’s interim CEO. We believe that his significant operational, development and product supply expertise will be crucial as we work towards completing the PARADIGME study and prepare for the planned filing for Betalutin with the FDA. On behalf of the Board I would like to thank Eduardo for his contribution as CEO."